Company news
Tme Pharma N.v. (EURONEXT:ALTME) news
Tme Pharma N.v. news releases on 6ix. Latest, Sep 16, 2026: TME PHARMA CEO MESSAGE
Press releases & updates
TME PHARMA CEO MESSAGE
September 16, 2026
MESSAGE DU CEO DE TME PHARMA
September 15, 2026
TME Pharma fait le point sur ses activités
August 23, 2026
Minutes of the TME Pharma Annual General Meeting
June 17, 2026
Compte-rendu de l’assemblée générale de TME Pharma
June 16, 2026
TME PHARMA ANNOUNCES CONVOCATION OF THE 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS
May 21, 2026
TME Pharma publishes its annual financial results and annual report
April 30, 2026
TME Pharma Announces Publication of NOX-A12 “Triple Therapy” Phase 1/2 Expansion Arm A Findings from GLORIA trial in Nature Communications
April 16, 2026
TME Pharma extends financial runway to over 12 months
March 9, 2026
TME Pharma provides update on its activities
January 5, 2026
TME Pharma announces receipt of agreements in principle to extend certain bond agreements
November 17, 2025
TME Pharma advances its new investment strategy and signs LOI with German resources company
November 5, 2025
TME Pharma N : 2025, Half-Year Financial Report as of 30 June 2025
October 31, 2025
TME Pharma publishes its semi annual results and half-year report
October 30, 2025
TME Pharma Announces Date of Publication of Half Year Results and CEO Share Purchase
September 22, 2025
TME Pharma Completes August Financing and Publishes Cash Position
September 1, 2025
TME Pharma to raise €500k through new bond issue and receives new notice of shareholding
August 25, 2025
TME Pharma Provides Update About Additional Strategy
July 29, 2025
TME Pharma: Termination of the Liquidity Contract
July 8, 2025
TME Pharma Announces New Treasury Investment Policy
June 30, 2025
TME Pharma Provides Results of Final Exercise of Warrants Z
June 27, 2025
TME Pharma Appoints Diede van den Ouden as New CEO at the 2025 Annual General Meeting of Shareholders
June 25, 2025
TME Pharma Announces Successful Next Step in Its NOX-E36 Ophthalmology Strategy With Signature of Option Framework Agreement With Singapore Eye Research Institute (SERI)
June 18, 2025
TME Pharma Provides Additional Details on the Debt and Warrant Agreements Announced on 21 May That Extend Its Financial Visibility by 12 Months
May 27, 2025
TME Pharma Announces Convocation of the 2025 Annual General Meeting of Shareholders
May 26, 2025
TME Pharma Extends Its Financial Visibility by 12 Months
May 21, 2025
TME Pharma Announces That Nominated CEO Plans to Increase His Shareholding
May 5, 2025
TME Pharma Announces New Strategy
May 5, 2025
TME Pharma Publishes 2024 Financial Results and Provides Operating Update
April 25, 2025